Should biologics for psoriasis be interrupted in the era of COVID-19?
作者信息
Lebwohl Mark, Rivera-Oyola Ryan, Murrell Dedee F
机构信息
Icahn School of Medicine at Mt Sinai Hospital, New York, New York.
Icahn School of Medicine at Mt Sinai Hospital, New York, New York.
出版信息
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
Abstract
摘要
相似文献
1
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
2
Should patients stop their biologic treatment during the COVID-19 pandemic.在新冠疫情期间，患者是否应该停止生物制剂治疗？
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
3
Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.初步数据表明，皮肤科使用的生物制剂与新冠肺炎不良结局无关。
J Cutan Med Surg. 2020 Jul/Aug;24(4):420-421. doi: 10.1177/1203475420929250. Epub 2020 May 25.
4
Asthma, biologics, corticosteroids, and coronavirus disease 2019.哮喘、生物制剂、皮质类固醇与2019冠状病毒病
Ann Allergy Asthma Immunol. 2020 Jul;125(1):12-13. doi: 10.1016/j.anai.2020.05.001. Epub 2020 May 6.
5
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.4例接受生物制剂治疗的银屑病患者的新型冠状病毒肺炎感染演变情况
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
6
Guttate psoriasis secondary to COVID-19.新型冠状病毒肺炎继发点滴状银屑病。
BMJ Case Rep. 2020 Aug 11;13(8):e237367. doi: 10.1136/bcr-2020-237367.
7
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素23通路抑制生物制剂治疗的银屑病患者发生呼吸道感染的风险：COVID-19大流行期间与决策相关的关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Nov;83(5):1523-1526. doi: 10.1016/j.jaad.2020.06.1014. Epub 2020 Jul 2.
8
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.患有少突胶质细胞瘤的红皮病型银屑病患者的COVID-19肺部感染：阿普米司特与重症监护管理的安全性和兼容性
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e376-e378. doi: 10.1111/jdv.16625. Epub 2020 Jun 4.
9
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
10
Psoriasis-COVID 19 Infection: Treatment Options.银屑病-新冠病毒感染：治疗选择
Skinmed. 2020 Mar 1;18(2):81-82. eCollection 2020.
引用本文的文献
1
Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.慢性炎症性皮肤病患者的疫苗接种率及免疫调节性全身治疗——针对严重急性呼吸综合征冠状病毒2、流感病毒或水痘带状疱疹病毒的疫苗接种
Life (Basel). 2024 Sep 12;14(9):1157. doi: 10.3390/life14091157.
2
Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest.接受全身治疗的银屑病患者对呼吸道感染的基本易感性：来自德国银屑病登记处PsoBest的数据。
J Clin Med. 2024 Jun 26;13(13):3713. doi: 10.3390/jcm13133713.
3
Identification of angiogenesis-related genes and molecular subtypes for psoriasis based on random forest algorithm.基于随机森林算法的银屑病血管生成相关基因和分子亚型的鉴定。
Clin Exp Immunol. 2024 Oct 16;218(2):199-212. doi: 10.1093/cei/uxae052.
4
Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.新冠疫情对银屑病患者的认知与影响：来自德国PsoBest和CoronaBest注册研究的数据
Psoriasis (Auckl). 2024 May 14;14:29-38. doi: 10.2147/PTT.S451666. eCollection 2024.
5
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks.使用司库奇尤单抗治疗新型冠状病毒肺炎后出现严重银屑病发作：16周后皮肤完全清除。
Dermatol Reports. 2023 Jun 6;16(1):9722. doi: 10.4081/dr.2023.9722. eCollection 2024 Mar 12.
6
Biologics protect psoriasis patients from being exacerbated by COVID-19 infection.生物制剂可保护银屑病患者免受新冠病毒感染的病情加重影响。
Heliyon. 2024 Jan 14;10(2):e24534. doi: 10.1016/j.heliyon.2024.e24534. eCollection 2024 Jan 30.
7
Psoriasis comorbidity management in the COVID era: a pressing challenge.新冠疫情时代银屑病合并症的管理：一项紧迫的挑战。
Front Microbiol. 2023 Nov 10;14:1294056. doi: 10.3389/fmicb.2023.1294056. eCollection 2023.
8
Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients.生物疗法可降低银屑病患者的疾病严重程度，并改善其抑郁和焦虑症状。
Life (Basel). 2023 May 19;13(5):1219. doi: 10.3390/life13051219.
9
Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies.不同 COVID-19 疫苗引发的免疫反应的复杂性，考虑到天然自身抗体和免疫调节疗法。
Int J Mol Sci. 2023 Mar 29;24(7):6439. doi: 10.3390/ijms24076439.
10
Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review.COVID-19大流行期间皮肤科的治疗依从性：一项综述
Cureus. 2023 Jan 24;15(1):e34141. doi: 10.7759/cureus.34141. eCollection 2023 Jan.
本文引用的文献
1
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.依奇珠单抗连续给药与间断治疗对比：两项银屑病3期试验的综合分析
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31.
2
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.聚乙二醇化 Fab' 依那西普治疗中重度斑块状银屑病的疗效：一项 II 期随机、安慰剂对照试验的结果及再治疗扩展研究。
Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.
3
Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept.中重度银屑病患者在接受依那西普重新治疗时会重新获得临床应答。
Br J Dermatol. 2009 Nov;161(5):1190-5. doi: 10.1111/j.1365-2133.2009.09238.x. Epub 2009 May 21.
4
The IL-12 family of cytokines in infection, inflammation and autoimmune disorders.感染、炎症和自身免疫性疾病中的白细胞介素-12细胞因子家族
Inflamm Allergy Drug Targets. 2009 Mar;8(1):40-52. doi: 10.2174/187152809787582507.
Zotero 插件